摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(cyclopropylmethyl)-6-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)piperazin-1-yl]-9-methyl-9H-purine-8-carboxamide | 1365606-95-6

中文名称
——
中文别名
——
英文名称
N-(cyclopropylmethyl)-6-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)piperazin-1-yl]-9-methyl-9H-purine-8-carboxamide
英文别名
N-(cyclopropylmethyl)-6-[4-(1,1-dioxo-1,2-benzothiazol-3-yl)piperazin-1-yl]-9-methylpurine-8-carboxamide
N-(cyclopropylmethyl)-6-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)piperazin-1-yl]-9-methyl-9H-purine-8-carboxamide化学式
CAS
1365606-95-6
化学式
C22H24N8O3S
mdl
——
分子量
480.55
InChiKey
WLDZBWKQQCZBSY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    34
  • 可旋转键数:
    5
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    134
  • 氢给体数:
    1
  • 氢受体数:
    8

文献信息

  • [EN] INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] INHIBITEUR DE PI3K-DELTA ET PROCÉDÉS D'UTILISATION ET DE FABRICATION CORRESPONDANTS
    申请人:EXELIXIS INC
    公开号:WO2012037226A1
    公开(公告)日:2012-03-22
    The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    这项发明涉及到式I的化合物及其药用可接受的盐或溶剂合物,以及制备和使用这些化合物的方法。
  • Processes for the preparation of abiraterone and related compouds
    申请人:Crystal Pharma, S.A.U.
    公开号:EP2607371A1
    公开(公告)日:2013-06-26
    The present invention relates to processes for obtaining abiraterone and derivatives thereof, such as abiraterone acetate, by means of a C-C coupling through a steroid hydrazone of general formula (II) or a Suzuki coupling through a steroid borate of general formula (IV), as well as to intermediates useful in said processes.
    本发明涉及通过类固醇缩酮(一般式(II))进行C-C偶联或通过类固醇硼酸酯(一般式(IV))进行Suzuki偶联的方法,以获得阿比特龙及其衍生物,如阿比特龙醋酸盐,同时涉及在该过程中有用的中间体。
  • [EN] TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS<br/>[FR] HYDROGÉNATION PAR TRANSFERT D'ANALOGUES DE CYCLOPAMINE
    申请人:INFINITY PHARMACEUTICALS INC
    公开号:WO2012037217A1
    公开(公告)日:2012-03-22
    Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.
    本文提供了一种用于转移氢化物的过程,适用于jervine型Veratrum生物碱酮类似物,如环状毒草碱。本文还提供了新颖的转移氢化催化剂。
  • TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS
    申请人:Infinity Pharmaceuticals, Inc.
    公开号:US20170029433A1
    公开(公告)日:2017-02-02
    Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.
    本文提供了一种将拟麻酮类似物,如环状毒草碱转移氢化的方法,例如环状毒草碱。本文还提供了新型的催化剂用于转移氢化反应。
  • Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture
    申请人:Kearney Patrick
    公开号:US20140058103A1
    公开(公告)日:2014-02-27
    The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
    这项发明涉及公式I的化合物:以及其药学上可以接受的盐或溶剂化物,以及制备和使用这些化合物的方法。
查看更多